About BAGIM

BAGIM is an active community of Boston area scientists bringing together people from diverse fields of modeling and informatics to impact life and health sciences. BAGIM strives to create a forum for great scientific discussions covering a wide range of topics including data management, visualization, computational chemistry, drug discovery, protein structure, molecular modeling, structure-based drug design, data mining, software tools, and the sharing of goals and experiences. Our community is made up of participants from academia, government, and industry whose goal is to engage in the discussion of science involving a synthesis of theory and technology. Discussions sponsored by BAGIM are targeted to the needs and interests of informatics scientists, computational chemists, medicinal chemists, and statisticians. BAGIM also provides opportunities for networking within these disciplines as well as an arena for the dissemination of information of specific interest to the membership.

Thursday, September 13, 2018

First BAGIM event of the season: Roy Vaz

Title: A data analysis exercise to decipher kinase antitargets

Roy J. Vaz received his Ph.D. from the University of Florida, Gainesville in Chemistry with Profs. G. B. Butler and M. Zerner. He obtained an undergraduate degree from the Indian Institute of Technology, Bombay. After his Ph.D., he obtained an MBA from the University of Illinois, UC and most recently an MS in Molecular Biology from Lehigh University. He was responsible for managing the CADD, SB and Cheminformatics efforts at Sanofi, Bridgewater, NJ prior to relocating and supporting small molecule discovery at Sanofi-Genzyme, Waltham, MA. He was previously Director of the Investigative Product Optimization department at Aventis in Bridgewater. He has worked with Bristol-Myers Squibb, Hopewell as Principal Scientist as well as Tripos, Inc, St. Louis as a Research Scientist. He has authored or co-authored over 50 publications in peer-reviewed journals, contributed towards many book chapter and several patents and edited 2 books related to Antitargets.

No comments:

Post a Comment